CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a Phase 1 clinical trial of its investigational oral multi-targeted kinase inhibitor, AP24534, in patients with refractory hematological cancers, including those with drug-resistant forms of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). This clinical study is designed to determine the safety and tolerability of AP24534, as well as its pharmacokinetics (the behavior of the drug in patients) and its pharmacodynamics (the effects of the drug on patients’ cells). Since all participants in the trial will have well-characterized malignancies, initial information describing the product candidate’s anti-tumor activity will also be obtained.
